[PP.07.20] CORRELATION OF POLYMORPHISM RS699 (G (-6) A) IN THE PROMOTER OF THE GENE CODING ANGIOTENSINOGEN AND EARLY MANIFESTATION OF HYPERTENSION. (September 2016)

• Record Type: Journal Article
• Authors: Chakalova-Yancheva, T.; Gospodinov, K.; Rashev, T.; Mladenova, Y.; Stancheva, N.; Tonchev, P.; Tisheva, S.
• Is Part Of: Journal of hypertension. Volume 34:(2016) Supplement 2
• Publication Date: 2016-09
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000491771.83014.e1
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: The objective of this study is to find the relationship between polymorphisms rs699 in the promoter angiotensinogen encoding a functional change in the final product, and the early manifestation of hypertension and the existence of the earlier target cardiac damage in young hypertensive patients. Design and method: The prospective study design includes a selection of the target group - young hypertensive patients aged 18–50 years with high blood pressure, defined as cases, and the control group includingsame age patients without hypertension. A questionnaire containing demographic, anthropometric and clinical data on the examined groups was used. Blood for genetic analysis was taken, and echocardiography was performed for studying target organs damage. The methods used for DNA analysis were TaqMan- PCR and PCR-HRM. An appropriate statistical analysis were (Fisher exact test, chi-square test, central tendency and descriptive statistics) done to compare groups. Results: The study showed that in a total of 78 subjects (48 young hypertensives and 30 controls) the frequency of the tested polymorphism was 59.0%. As 70.8% (34 patients) of young hypertensive patients werecarriers of rs699 and only 40% (12 patients) in the control group hadthe same polymorphism. RR(risk ratio) for early hypertension in rs699 carriers is eRR = 1.69 (1.15–2.48), p = 0.01 (Fisher exact test). Analysis of data from surveys and echocardiography showed that 96% of young hypertensive carriers of this polymorphism had hypertension onset of about 30 years had expressed LVH and diastolic dysfunction. Conclusions: Our results showed that the frequency of rs699 polymorphism was significantly higher in young hypertensive patients with essential hypertension compared with none-hypertonic in the same age. Also, the presence of this SNA polymorphism in the genome was associated with an earlier manifestation of hypertension and earlier target heart damage.